ICTM logo
CROI Conference 2018

08 March 2018

Sunday 4 March marked the beginning of the CROI Conference 2018, where the MRC Clinical Trials Unit at UCL presented results from several HIV trials, including REALITY, CHER, and START.
 
CROI is a global model of collaborative science and the premier international venue for bridging basic and clinical investigation to clinical practice in the field of HIV and related viruses.

CROI 2018 took place from Sunday 4 March to Wednesday 7 March, in Boston, Massachusetts, at the Hynes Convention Center.
 
Details of the MRC CTU at UCL presentations that took place at CROI 2018 are shown below.

Day

Time

Type

Title

Authors

Location

05 March 2018

10:15 - 10:30

Oral Abstract session

23 - Impact of Raltegravir Intensification of First-Line ART on Iris in The REALITY Trial

Gibb, D

Auditorium Front Section

05 March 2018

14:30 - 16:00

Poster session

490 - Mortality/Morbidity after Initiating ART with CD4 <100 Cells/Ul in the REALITY Trial

Post, F

Poster Hall D

05 March 2018

14:30 - 16:00

Poster Session

847 - Self-Harm in Adolescents with Perinatal HIV and HIV-Affected Adolescents in England

Copelyn, J

Poster Hall D

05 March 2018

14:30 - 16:00

Poster session

896 - Late Presentation with HIV in Africa: Phenotypes, Risk and Risk Stratification

Gibb, D

Poster Hall B

06 March 2018

10:00 - 10:15

Oral Abstract session

74 - Il-6, D-Dimer or T-Cells: Which Best Predict Events or Explain Benefits of Early ART?

Baker, J

Ballroom A

06 March 2018

14:30 - 16:00

Poster session

864 - Factors Associated with HIV DNA Levels in Children Starting ART Early in Infancy

Chan, M

Poster Hall D

06 March 2018

14:30 - 16:00

Poster session

531 - Effect of 12-Week Raltegravir-Intensification of First-Line ART on HIV Resistance

Kityo, C

Poster Hall D

06 March 2018

14:30 - 16:00

Poster session

853 - Are HIV+ Migrant Children in Europe at Increased Risk of Poor Outcomes on ART?

Collins, IJ

Poster Hall D

06 March 2018

14:30 - 16:00

Poster session

784 - CRAG Status and Effect on Benefits from Enhanced Prophylaxis in the REALITY Trial

Pett, S

Poster Hall D

07 March 2018

10:30 - 10:45

Oral Abstract session

137 - Time to Viral Rebound after Stopping ART in Children Treated from Infancy in CHER

Chan, M

Ballroom C

07 March 2018

13:30 - 14:30

Poster Themed Discussion

784 - CRAG Status and Effect on Benefits from Enhanced Prophylaxis in the REALITY Trial

Pett, S

Ballroom B


There were also press conferences following 'Impact of Raltegravir Intensification of First-Line Art on Iris in The Reality Trial' and 'Time to Viral Rebound after Stopping ART in Children Treated from Infancy in CHER'.


Raltegravir does not increase the incidence of IRIS

Results from the REALITY trial, presented at CROI, show that the use of raltegravir, an anti-HIV drug, did not increase the number of patients getting Immune Reconstitution Inflammatory Syndrome (IRIS).

IRIS is seen in patients with HIV starting treatment for their condition. As the immune system starts to recover, it begins to fight other infections that the patient already has; this causes an inflammatory response that makes the diseases' symptoms worse.

It was previously thought that IRIS might be more common in patients treated with raltegravir, and other drugs in the same class (integrase inhibitors). Integrase inhibitors are now replacing other anti-HIV drugs as first-line treatment.

Following presentation of the REALITY results, Diana Gibb confirmed that: "The increase in [the number of patients with] IRIS is not there with integrase inhibitors. In other words, they are safe to use on a global level."

Diana Gibb highlighted that one of the interventions in the REALITY trial, a low-cost package of drugs to prevent several other infections, significantly reduced the number of people getting IRIS. The package of drugs also reduced overall deaths by 27%, a finding published last year in the New England Journal of Medicine.